GLP-1 taper schedule: what stepping down actually looks like

No. The 2026 literature states directly that no evidence-based protocols currently guide GLP-1 de-escalation, and that patients report self-directed experimentation with alternative dosing. What exists instead: label-permitted maintenance reductions (Wegovy explicitly allows a permanent drop from 2.4mg to 1.7mg; Zepbound names 5, 10 and 15mg as maintenance doses), a February 2026 case series describing structured de-escalation as feasible in selected patients, and widespread clinical practice of stepping down. This tool shows those patterns; it does not invent a protocol.

The pattern most commonly described in clinical write-ups mirrors titration in reverse: drop one rung of the approved ladder roughly every four weeks, which gives appetite time to adjust at each level before the next drop. For Wegovy that path runs 2.4 to 1.7 to 1.0 to 0.5 to 0.25mg. Some clinicians go slower, some hold at a lower maintenance dose indefinitely rather than reaching zero. No randomized trial has compared these against each other, so the specific schedule is a prescriber decision based on your history, appetite response, and goals.

In practice, anywhere from a couple of months to most of a year, depending on your starting dose and how many rungs you step through. A four-week-per-step taper from Zepbound 15mg is roughly 20 weeks to zero; the same pattern from Wegovy 2.4mg is about 16 weeks. Holding at a lower maintenance dose has no endpoint at all, which is a legitimate outcome rather than a failed taper. Longer tapers cost more in medication and extend side effects, so slower is a trade, not automatically better.

Unproven, and worth being precise about. What is established: stopping abruptly without support led to about two-thirds of lost weight returning within a year in trial extensions. What is emerging: a Feb 2026 case series found patients maintaining weight and metabolic markers through structured de-escalation, and a tapering-with-coaching cohort stayed weight-stable six months after stopping. What is unproven: that tapering itself beats stopping abruptly. Most clinicians favor it, no trial has demonstrated it, and in both the case series and the coaching cohort there was behavioral support alongside the taper.

It changes the height you fall from, not the clearance speed. Half-life is fixed: about 7 days for semaglutide, 5 for tirzepatide. If you stop from a high dose, your steady level drops from its maximum and the full appetite transition arrives in one 3 to 6 week window. If you step down first, each drop is smaller and you meet the transition in slices, with weeks to adjust eating structure between them. Same destination, different slope.

Extending the interval between doses is a real strategy, sometimes called reduced-frequency dosing, and the Feb 2026 case series included it. Because these molecules have 5 to 7 day half-lives, spacing doses lowers your average level between shots. It is off-label, has no randomized trial behind it, and is a different thing from lowering the dose itself. The important variable in every published discussion of it is supervision, so it belongs in a prescriber conversation rather than a solo experiment with your remaining pens.